Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved niraparib and abiraterone acetate with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.
The indication requires an FDA-approved test, keeping genetic testing at the centre of treatment eligibility.
The approval is another example of DNA-repair biology shaping prostate-cancer treatment, not only breast and ovarian cancer care.
Why It Matters
Precision oncology continues to move across tumour types as inherited and acquired DNA-repair mutations guide therapy.
What to Watch
Watch testing access and sequencing with other prostate-cancer systemic therapies.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAProstate CancerBRCA2Precision Oncology